Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04607850
Recruitment Status : Recruiting
First Posted : October 29, 2020
Last Update Posted : March 19, 2021
Sponsor:
Information provided by (Responsible Party):
Vaccitech Limited

Brief Summary:
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

Condition or disease Intervention/treatment Phase
HPV Biological: ChAdOx1-HPV Biological: MVA-HPV Biological: Placebo Phase 1 Phase 2

Detailed Description:

The study consists of an open label, non-randomised, dose escalation Lead in phase. 9 participants with high-risk HPV, in cohorts of 3 in 3 dose ascending groups, will be vaccinated after SMC safety data reviews.

This is followed by a blinded, randomised Main phase with 96 participants with high-risk HPV, in parallel running dose cohorts (three different doses of ChAdOx1-HPV plus two different doses of MVA-HPV versus placebo plus placebo boost). At least 60 of these participants will take part in the immunogenicity sub-study.

A blinded, randomised expansion phase investigating the effects of up to two different main phase doses against placebo will be further defined prior to commencing this phase of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Lead in phase will be open label. Main phase and expansion phase will be blinded.
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions
Actual Study Start Date : March 16, 2021
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022

Arm Intervention/treatment
Experimental: Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Experimental: Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
Biological: ChAdOx1-HPV
Trial vaccine

Biological: MVA-HPV
Trial vaccine

Placebo Comparator: Group 6 Placebo Saline
Sodium Chloride (0.9%)
Biological: Placebo
Saline placebo vaccine




Primary Outcome Measures :
  1. Incidence of adverse events to measure safety and reactogenicity [ Time Frame: 3 months for the lead-in and 12 months for the main phase ]
    Measure of adverse events, serious adverse events (SAEs), ≥Grade 3 study vaccine-related adverse events reported.


Secondary Outcome Measures :
  1. Determine the dose of ChAdOx1-HPV plus MVA-HPV vaccines for further development [ Time Frame: 3 months for lead in phase and 12 months for main phase ]
    Measurement of the highest multi-parameter index made of CD4+ magnitude, CD4+ avidity and CD8+ magnitude at peak timepoint

  2. Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on the clearance of high risk HPV infection [ Time Frame: 12 months for main phase only ]
    The percentage of hrHPV infection clearance

  3. Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on cervical intraepithelial neoplasia (CIN) [ Time Frame: 12 months for main phase only ]
    The percentage of cervical lesions cleared as determined by colposcopy


Other Outcome Measures:
  1. Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines [ Time Frame: 3 months for lead in phase and 12 months for main phase ]
    This will be assessed by measuring the individual phenotypic subsets of CD4+ and CD8+ T cells induced by vaccination

  2. Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines [ Time Frame: 3 months for lead in phase and 12 months for main phase ]
    This will be assessed by measuring the innate immune response after vaccination compared to baseline

  3. Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines [ Time Frame: 3 months for lead in phase and 12 months for main phase ]
    This will be assessed by measuring the T cell breadth of response to the components of the ChAdOx1-HPV plus MVA-HPV vaccines

  4. Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines [ Time Frame: 3 months for lead in phase and 12 months for main phase ]
    Immune responses after prime and boost vaccinations in cytobrush samples compared to baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Participants must have a cervix in order to participate.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females aged ≥25 and ≤55 years of age at screening.
  • Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result.
  • Low-grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening.
  • Not pregnant or breast feeding and one of the following:

    • Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause)
    • Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:
  • Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant
  • Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective.
  • An intrauterine hormone-releasing system
  • An intrauterine device
  • Bilateral tubal occlusion
  • Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures.

Exclusion Criteria:

  • Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias.
  • Immunosuppression as a result of underlying illness or treatment including:

    • Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for ≥7 days (inhaled, otic and ophthalmic corticosteroids are permitted)
    • Primary immune deficiency disease
    • Use of synthetic or biologic disease-modifying antirheumatic drugs
    • History of bone marrow or solid organ transplant
    • History of any other clinically significant autoimmune or immunosuppressive disease
  • Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection.
  • Evidence of high-grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening.
  • Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine.
  • Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine.
  • Any history of receipt of any adenoviral or MVA-based vaccine.
  • Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination.
  • Current or history of illicit drug use within the 6 months prior to screening.
  • Current or history of severe alcohol abuse within the 6 months prior to screening.
  • Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study.
  • Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as evidenced by PCR laboratory testing.
  • Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04607850


Contacts
Layout table for location contacts
Contact: General Enquiries (+44) 1865818808 enquiries@vaccitech.co.uk

Locations
Layout table for location information
Belgium
UZA Not yet recruiting
Antwerp, Belgium, 2650
Contact: Wiebren Tjalma, MD       Wiebren.Tjalma@uza.be   
Erasme Hospital Recruiting
Brussels, Belgium, 1070
Contact: Francoise Henry       Francoise.henry@erasme.ulb.ac.be   
UZ Brussel Not yet recruiting
Brussels, Belgium, 1090
Contact: Philippe DeSutter, MD       Philippe.DeSutter@uzbrussel.be   
UZ Gent Not yet recruiting
Gent, Belgium, 9000
Contact: Isabel Leroux-Roels, MD       cevac@uzgent.be   
United Kingdom
University Hospital Bristol NHS Trust Not yet recruiting
Bristol, United Kingdom, BS2 8EG
Contact: Claire Newton, MD       research_st.michaels@uhbristol.nhs.uk   
University Hospital of North Durham Not yet recruiting
Durham, United Kingdom, DH1 5TW
Contact: Partha Sengupta, MD       mwood8@nhs.net   
Liverpool Women's NHS Foundation Trust Not yet recruiting
Liverpool, United Kingdom, L8 7SS
Contact: Paula Briggs, MD       research@lwh.nhs.uk   
Saint Mary's Hospital Not yet recruiting
Manchester, United Kingdom, M13 9WL
Contact: Ursula Winters, MD       Gynaecology.Research@mft.nhs.uk   
Royal Victoria Infirmary Not yet recruiting
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Contact: Michelle Russell, MD       michelle.russell5@nhs.net   
Nottingham University Hospital NHS Trust Not yet recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Ketankumar Gajjar       ObsGynaeResearch@nuh.nhs.uk   
The University of Oxford, Nuffield Department of Women's & Reproductive Health Not yet recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Isabella Sereni, MD       hpv-study@wrh.ox.ac.uk   
Contact: Sereni, MD         
Royal Preston Hospital Not yet recruiting
Preston, United Kingdom, PR2 9HT
Contact: Pierre Martin-Hirsch, MD       Pierre.Martin-Hirsch@lthtr.nhs.uk   
Sponsors and Collaborators
Vaccitech Limited
Layout table for additonal information
Responsible Party: Vaccitech Limited
ClinicalTrials.gov Identifier: NCT04607850    
Other Study ID Numbers: HPV001
First Posted: October 29, 2020    Key Record Dates
Last Update Posted: March 19, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No